For instance, anti-EGFRvIII antibodies, such as mAb 806 and CH12, which selectively bind to a cancer-specific epitope of EGFR or EGFRvIII, have been demonstrated to be capable of efficiently inhibiting the growth of EGFRvIII-positive tumor xenografts [21, 25, 26]. The gene discussed is EGFR; the disease is neoplasm.